Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 130Lenalidomide 82daratumumab 60Bortezomib 56carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 31isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15fludarabine 13Melphalan 13iberdomide 11elotuzumab 11selinexor 10fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mass Screening × Plasma cell × Clear all
NCT05844033 2026-05-19

Biomarker for Infection Risk in CLL and MM

Massachusetts General Hospital

Active not recruiting
150 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡